GLP1R and heart failure: Oral semaglutide shows no significant difference compared with other GLP-1 receptor agonists in the incidence of MACE, in hospitalization for heart failure, and no difference on cardiovascular death (except for Lixisenatide: HR 0.5; CI 95% 0.26–0.96) [68].